Azithromycin alleviates systemic lupus erythematosus via the promotion of M2 polarisation in lupus mice.
Ontology highlight
ABSTRACT: Our previous study demonstrated that azithromycin could promote alternatively activated (M2) macrophages under lupus conditions in vitro, which might be beneficial for lupus treatment. Thus, the aim of this study was to further confirm whether azithromycin can drive M2 polarisation in lupus and ultimately alleviate systemic lupus erythematosus (SLE) in vivo. Lymphocyte-derived DNA (ALD-DNA)-induced mice (induced lupus model) and MRL-Faslpr mice (spontaneous lupus model) were both used in the experiment. First, we observed symptoms of lupus by assessing the levels of serum anti-dsDNA antibodies and serum creatinine and renal pathology. We found that both murine models showed increased levels of serum anti-dsDNA antibodies and creatinine, enhanced glomerular fibrosis and cell infi
SUBMITTER: Wang J
PROVIDER: S-EPMC8050155 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA